Stockpolly
Search
KLRS · NASDAQ · Biotechnology

Kalaris Therapeutics (KLRS)

Develops TH103 for neovascular and exudative retinal diseases.

$3.76
Pre-market−0.14 (−3.60%)
At close$3.90(−0.50%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue400000000000
Gross profit−400000000000
433343820101213111212
Research & development31323360689789
13011219444443
General & administrative001120444003
Operating income−47−3−3−4−38−20−10−12−13−11−12−12
30−1−101011111
Interest income200001000000
Interest expense000010100000
Other non-operating income−3011−1−1−2−1−1−1−10
Income before tax−44−3−3−6−38−18−10−11−12−10−11−12
Net income from continuing operations−44−3−3−6−38−18−10−11−12−10−11−12
Net income−44−3−3−6−38−18−10−11−12−10−11−12
EPS, basic−$8.94−$0.70−$0.68−$1.13−$7.64−$3.64−$2.52−$0.61−$0.64−$0.44−$0.46−$0.48
EPS, diluted−$8.94−$0.70−$0.68−$1.13−$7.64−$3.64−$2.52−$0.61−$0.64−$0.44−$0.46−$0.48
Weighted average shares, basic55555541919232424
Weighted average shares, diluted55555541919232424
EBITDA−41−3−3−5−37−18−9−11−12−10−11−12
Depreciation & amortization400000000000
EBIT−44−3−3−5−37−18−9−11−12−10−11−12